Learn More
OBJECTIVE Glioblastoma multiforme (GBM) accounts for up to 60% of all malignant primary brain tumours in adults, occurring in 2-3 cases per 100,000 in Europe and North America. In 2005, a Phase III clinical trial demonstrated a significant improvement in survival over 2, and subsequently 5, years with the addition of concurrent and adjuvant temozolomide(More)
INTRODUCTION Description of the cutaneous side effects of erlotinib. MATERIALS Report with images of a single case. METHODS Case report and review of the literature. CONCLUSION Erlotinib is associated with significant cutaneous toxicity which should be recognised and managed appropriately.
e12512 Background: Glioblastoma Multiforme (GBM) is the most common primary brain tumour in adults. The most recent figures from the National Cancer Registry of Ireland revealed 180 new cases of GBM diagnosed in Ireland in 2008. In 2005 a phase III clinical trial demonstrated a significant improvement in survival over two and subsequently five years with(More)
e13032 Background: North American studies have demonstrated an increase in incidence of primary CNS lymphoma in recent decades. To our knowledge there have been no studies analyzing primary CNS lymphoma in the Irish setting. This prompted a review of cases diagnosed at our institution, the larger of two national neurosurgical/neuro-oncology referral(More)
  • 1